Morgan Stanley Kazia Therapeutics LTD Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Kazia Therapeutics LTD stock. As of the latest transaction made, Morgan Stanley holds 197,850 shares of KZIA stock, worth $45,505. This represents 0.0% of its overall portfolio holdings.

Number of Shares

197,850

Previous 201,550 1.84%

Holding current value

$45,505

Previous $88,000 30.68%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.2 - $0.45 $740 - $1,665	-3,700 Reduced 1.84%	197,850 $61,000
Q4 2023 Feb 13, 2024	BUY	$0.39 - $0.99 $4,524 - $11,484	11,600 Added 6.11%	201,550 $88,000
Q3 2023 Nov 15, 2023	SELL	$0.84 - $1.17 $12,264 - $17,082	-14,600 Reduced 7.14%	189,950 $189,000
Q2 2023 Aug 14, 2023	BUY	$1.03 - $1.55 $5,253 - $7,905	5,100 Added 2.56%	204,550 $237,000
Q1 2023 May 15, 2023	SELL	$0.73 - $1.16 $42,260 - $67,153	-57,891 Reduced 22.5%	199,450 $205,000

Q4 2022 Feb 14, 2023	BUY	$0.5 - $0.7 $26,445 - $37,023	52,891 Added 25.87%	257,341 $156,000
Q3 2022 Nov 14, 2022	BUY	$1.13 - $4.19 $3,214 - $11,920	2,845 Added 1.41%	204,450 $224,000
Q2 2022 Oct 27, 2022	SELL	$4.1 - $8.38 $376,261 - $769,040	-91,771 Reduced 31.28%	201,605 $846,000
Q2 2022 Aug 15, 2022	SELL	$4.1 - $8.38 $376,261 - $769,040	-91,771 Reduced 31.28%	201,605 $846,000
Q1 2022 Oct 27, 2022	BUY	$6.05 - $8.65 $555,214 - $793,819	91,771 Added 45.52%	293,376 $2.26 Million
Q1 2022 May 13, 2022	SELL	$6.05 - $8.65 $36,602 - $52,332	-6,050 Reduced 2.02%	293,376 $2.26 Million
Q4 2021 Feb 14, 2022	BUY	$7.35 - $12.0 $88,788 - $144,960	12,080 Added 4.2%	299,426 $2.52 Million
Q3 2021 Nov 15, 2021	BUY	$8.65 - $11.64 $2.49 Million - $3.34 Million	287,346 New	287,346 $3.25 Million

Others Institutions Holding KZIA

# of Institutions

Shares Held

323K

Call Options Held

Put Options Held

View Full List

About KAZIA THERAPEUTICS LTD

Ticker KZIA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,111,300
Market Cap $3.48M
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...

More about KZIA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account